Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer

NCT01784978 is registered in ClinicalTrials.gov with Associació per a la Recerca Oncologica, Spain as lead sponsor.

NCT NCT01784978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01784978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer
Lead sponsor
Associació per a la Recerca Oncologica, Spain
Phase
Phase 2
Overall status
Terminated
Start date
February 12, 2013
Completion date
May 8, 2017
Enrollment
41 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma